Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing

Key Points

• Thermo Fisher Scientific has introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor for scalable cell therapy manufacturing.
• The system is designed to support cell expansion from process development through cGMP-ready clinical production, for a range of applications including cancer and autoimmune programs. It’s also integrated into Thermo Fisher’s broader CTS workflow.

Platform Overview

Thermo Fisher Scientific has introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a stirred-tank platform built to support cell expansion across process development and early clinical manufacturing. The company says the system is designed to help developers move from smaller development batches to larger cGMP-ready runs while maintaining flexibility and process control.

The launch addresses a common manufacturing challenge in cell therapy. As programs move toward clinical development, teams often need to shift away from static culture systems and into platforms that can better support scale, automation, and more consistent production.

Fit for Emerging Cell Therapy Programs

Today’s cell therapy pipeline extends beyond oncology to include autoimmune disease and other emerging indications, requiring different manufacturing configurations, scales, and workflows that add complexity across development and production.

According to the company, the CTS DynaXS Single Use Bioreactor was designed with that variability in mind. It is intended to support a broad range of volumes, applications, and cell types, giving developers a more flexible option for expansion as manufacturing needs change over time.

Integration With the CTS Ecosystem

The bioreactor extends Thermo Fisher’s Cell Therapy Systems (CTS) portfolio, which includes tech for cell isolation, activation, expansion, and downstream processing. The integrated approach can now support modular manufacturing strategies and provide unified technical support and regulatory documentation.

“Manufacturers want platforms that grow with them,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types.”

You can request more information here.

Want to keep up on regenerative medicine? Get the weekly newsletter here.